The familiar argument pharma marketers have used for years to justify their huge DTC advertising budgets is that DTC creates awareness, awareness gets patients into the doctor’s office, and patient requests ultimately lead to prescriptions. There is some truth to that. The trouble is that the financial return behind that model appears to be deteriorating at an extraordinary rate. I think one number should get a lot more attention inside pharma marketing departments.
Specialty drugs launched in 2013 by IQVIA generated around $85 in gross sales for every $1 spent on DTC advertising in their first two years on the market. For specialty products launched in 2022, that ratio had fallen to about 1:1.Nine specialty brands launched in 2022 contributed nearly $1.3 billion in combined gross sales over their first 24 months, while spending nearly $1.1 billion on DTC.
This is not net revenue minus advertising costs. It’s gross sales versus DTC spend. Before rebate. Price before discounts. Before sales-force expenses. Before patient support programs. Before medical affairs. Before costs of market access. Before the rest of the huge infrastructure needed to commercialize a specialty drug.
This makes the fall from 85:1 to about 1:1 a lot harder to dismiss as just another complaint about annoying drug ads. It’s a commercial productivity issue.
And still the spending machine keeps rolling.
Pharma companies spent more than $6 billion on DTC television advertising alone in 2024, according to IQVIA, with 75 brands spending at least $10 million apiece. IQVIA estimates that drugmakers have spent just under $50 billion on television DTC over the last decade. Meanwhile, average cumulative DTC investment over the first 36 months was about 21% higher for products launched from 2019–2022 than for products launched from 2015–2018. Today, a typical launch spends about $169 million on DTC media in the first three years versus $140 million before.
Thus, when efficiency has fallen, the answer has often been to spend more.
DTC still works. That’s what makes this so hard.
It’s easy to look at those numbers and say DTC advertising is dead. That would be wrong too.
IQVIA reports that specialty launches spending $1 million or more on DTC had, on average, nearly double the number of patients per treating provider in year one than brands spending little or nothing on DTC. The advantage five years after launch was still about 45%; DTC can clearly generate patient interest and boost the patient productivity per physician.
More evidence shows advertising affects behavior. One in ten of the 148,000 gastroenterology treatments IQVIA analyzed included a patient request. More than 80% of these requests resulted in a prescription, although not always for the drug requested.
So the question is not if DTC can move people.
The question is pharma paying way too much to get them to move.
The answer is increasingly looking like yes. For launches in 2022, IQVIA estimates DTC spending per patient start averaged about $13,000 in the first 24 months versus about $2,700 for 2018 launches — roughly a 375% increase. Some brands paid over $80,000 in DTC per acquired patient. Reach is a marketing accomplishment until the economics don’t work.
Pharma has an advertising problem, not an efficiency problem
The industry needs to stop treating DTC budgets as an entitlement passed down from last year’s brand plan. Far too many plans still begin with a media budget and work backward: *We have $80 million. What is the best media mix?*
A better question is: What is a commercially rational price to pay to acquire an incremental patient? The calculation should be on net patient value, not gross sale. It should consider expected persistence, rebates and discounts, payer mix, abandonment, adherence, treatment duration, and how likely the advertising was to have actually caused the incremental start.
An incremental patient is worth $10,000 in contribution and costs $15,000 in media to acquire. Spending another $10 million on advertising doesn’t solve the problem. It makes the problem $10 million bigger.
Stop buying patients who cannot get the drug.
This could be one of the biggest wastes of pharma DTC. An ad can be brilliant. The targeting can be flawless. The patient can visit the brand website, download the discussion guide, make an appointment, and in particular ask the physician about the advertised product.
And then the payer says no. Knowing without access is expensive frustration.
In particular, IQVIA points to access and affordability barriers as factors driving the declining efficiency of DTC. But media planning and market-access planning can still be largely independent disciplines. They don’t have to.
Before increasing DTC in a geographic market, brands need to understand formulary coverage, payer mix, rejection rates, abandonment, out-of-pocket burden, and fulfillment friction. Increasingly, media investment should be driven by commercial access, not just audience availability.
Replace reach with qualified patient acquisition.n
Pharma marketers love big numbers: impressions, reach, video completion rates, website visits, brand awareness. They don’t pay the bills.
An improved DTC dashboard would further track the patient through the funnel:
Exposed > engaged > physician visit > diagnosis > prescription > approval > fill > adherence > incremental net revenue.
The more marketers can connect advertising investment to that sequence, within the bounds of privacy and regulation, the less they depend on media metrics that may look nice in PowerPoint presentations but tell you little about commercial performance.
The goal shouldn’t be the cheapest impression. It should be the least sustainable cost per incremental qualified patient.
Don’t market to everyone who technically fits the condition
Mass reach made sense when TV audiences were huge, media was relatively inexpensive, and fewer competitors in the pharmaceutical categories were trying to get attention. That world is vanishing.
Precision is the better chance. Disease severity, treatment history, physician availability, payer coverage, geography, likelihood to seek care, and other permissible signals can help identify populations where advertising has a realistic chance to change behavior.
Digital channels also enable faster measurement and optimization. IQVIA estimates that healthcare advertising spend on digital channels will exceed $23 billion in 2025, a 33% increase from 2022 levels, with connected TV, online video, digital audio and other channels offering more sophisticated measurement and targeting capabilities.
But taking money from TV and putting it into digital isn’t innovation. Programmatic bad targeting is still bad targeting. Here’s the truth about advertising: it can’t save a bad product story.
Perhaps the industry’s most uncomfortable lesson about DTC. But if patients don’t understand why a new therapy is meaningfully different, increasing frequency won’t necessarily solve the problem.
The same is true for doctors. If the clinical value proposition isn’t compelling enough, consumer demand eventually hits a wall at the door of the exam room.
That’s why a DTC strategy should be built on a brutally simple question:
What would motivate a patient who is fairly happy with their current treatment to do something?
More effective? Less side effects? Easier to administer? Reduced dosing frequency? An actual improvement in quality of life? A treatment option for patients who have not responded well to current therapies?
If it’s not clear, dropping another $30 million to tell the same story louder probably isn’t the answer. Test smaller. Learn quicker. Scale what works.
Pharma has a strange marketing habit of spending huge budgets before adequately proving incremental return.
Consumer marketers test audiences, creative, offers, and channels all the time, then quickly shift money to the combinations that work best. The regulatory environment for pharma makes the optimization more complicated, but doesn’t eliminate the need for experimentation.
Create geographic or audience test cells where possible, establish control populations, measure incremental patient starts (not raw prescription volume), track cost per incremental patient, and set predetermined thresholds for increasing or reducing investment.
The budget is not sacrosanct. Evidence must determine the budget.
It also means agencies should not be rewarded primarily for efficiently deploying huge media allocations. Commercial organizations should align incentives more and more around incremental outcomes and measurable productivity.
DTC must be part of the patient experience
Ask your doctor. The next generation of DTC should not stop there. And that’s when the commercial journey begins.
A patient may be motivated enough to respond to an advertisement. However, they still have to find the right physician, wait for an appointment, navigate prior authorization, figure out insurance coverage, understand out-of-pocket costs, find a specialty pharmacy, and stay on treatment.
Every extra step causes leakage.
So the best DTC strategy may not be another advertisement. It could be better tools for finding a physician, clearer information about coverage, faster benefit verification, more useful patient education, stronger onboarding, or a better support experience. Marketing ROI is not simply about generating more demand, but about **losing fewer patients after demand has been generated. ****
The 85:1 era is not coming back.
One other uncomfortable reality underlies these numbers. The pharmaceutical marketplace today is more crowded, access is more complicated, media is more expensive, and patients have almost infinite competition for their attention. Saturated media, rising ad costs, and higher barriers to market access are the key drivers behind the drop in DTC returns, according to IQVIA itself.
That’s not to say that pharma companies shouldn’t advertise. It means they shouldn’t assume advertising is entitled to the budget just because it always had it. With a gross sales-to-DTC spend ratio of 85:1, you can pay for a lot of marketing inefficiency. No ratio anywhere near 1:1 can. And maybe that’s good for pharma marketing in the long run.
It forces organizations to trade reach for incrementality, gross sales for net patient economics, broad audiences for qualified patients, annual media commitments for continuous optimization, and isolated advertising campaigns for an integrated patient journey connecting **awareness, HCP engagement, access, fulfillment and persistence**.
DTC is not dead.
But the time when pharma could spend hundreds of millions of dollars on media and expect sales to justify it should be over. The next competitive advantage will not belong to the company that spends the most on DTC. It will belong to the company that can prove to the penny where the next dollar of DTC creates incremental value, and has the discipline not to spend it when it doesn’t.
